データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
300-39-0N[C@@H](Cc1cc(I)c(O)c(I)c1)C(=O)ONYPYHUZRZVSYKL-ZETCQYMHSA-N300-39-0DTXSID0048680CHEMBL1236469CHEBI:157680.617 mg/mL at 25 °C
>64.9 [ug/mL] (The mean of the results at pH 7.4)
159.3 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)];165.2 Ų [M+Na]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)];171.1 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
This chemical does not meet GHS hazard criteria for 14.3% (2 of 14) of reports.
Warning
H315 (85.7%): Causes skin irritation [Warning Skin corrosion/irritation];H319 (85.7%): Causes serious eye irritation [Warning Serious eye damage/eye irritation];H335 (85.7%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 14 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.;Reported as not meeting GHS hazard criteria per 2 of 14 reports by companies.;There are 3 notifications provided by 12 of 14 reports by companies with hazard statement code(s).;Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
H - Systemic hormonal preparations, excl. sex hormones and insulins;H03 - Thyroid therapy;H03B - Antithyroid preparations;H03BX - Other antithyroid preparations;H03BX01 - Diiodotyrosine
QH - Systemic hormonal preparations, excl. sex hormones and insulin;QH03 - Thyroid therapy;QH03B - Antithyroid preparations;QH03BX - Other antithyroid preparations;QH03BX01 - Diiodotyrosine
用途有機合成原料、医薬原料。
説明Diiodotyrosine does not possess pronounced hormonal activity. However, it stops production of thyrotropic hormone by the anterior lobe of the hypophysis, which activates thyroid gland activity.
使用It is used for hyperthyroid forms of endemic and sporadic goiters, diffuse, toxic goiters, and other illnesses accompanied by thyrotoxicity.
純化方法It forms crystals from H2O [solubility (g/L): 0.204 at 0o, 1.86 at 50o, 5.6 at 75o and 17.0 at 100o]. Also recrystallise it from 50% or 70% EtOH. When boiled in EtOH the crystals swell, and on further boiling a gelatinous precipitate is formed [Harrington Biochem J 22 1434 1928, Jurd J Am Chem Soc 77 5747 1955]. It also crystallises from cold dilute ammonia on adding acetic acid to pH 6. [Beilstein 14 IV 2370.]
読み込み中…
化学的特性white to beige powder
定義ChEBI: A diiodotyrosine that is L-tyrosine carrying iodo-substituents at positions C-3 and C-5 of the benzyl group. It is an intermediate in the thyroid hormone synthesis.